PatentVest (@PatentVest) header
PatentVest (@PatentVest) profile picture

The first IP intelligence and strategy firm helping visionary companies become tech leaders. A subsidiary of MDB Capital Holdings (NASDAQ: MDBH)

Dallas, Texas 75229, US
Joined October 2025
Photo by PatentVest (@PatentVest)Photo by PatentVest (@PatentVest)Photo by PatentVest (@PatentVest)Photo by PatentVest (@PatentVest)Photo by PatentVest (@PatentVest)Photo by PatentVest (@PatentVest)Photo by PatentVest (@PatentVest)Photo by PatentVest (@PatentVest)Photo by PatentVest (@PatentVest)
Who actually invented your invention? As AI and distributed R&D reshape innovation, proving inventorship and ownership is becoming increasingly important. Will Rosellini explains why invention provenance matters for protecting IP. Link to full article 👇👇👇
1
13
Can OpenAI patent ChatGPT? Everyone says @OpenAI has no patent moat. We analyzed 69 published patent families to see if that's true. The answer may surprise you, and so might how its strategy compares with @AnthropicAI. Read more: insights.patentvest.com/open… #OpenAI #Patents
26
Everyone is still talking about GLP-1. Big Pharma is investing in what's next. Novo Nordisk, @Roche, and GSK committed $10.7B to FGF21 in just six weeks. Why? Find out what's driving the next cardiometabolic opportunity: insights.patentvest.com/how-… #FGF21 #GLP1 #Biotech #Pharma
39
Lilly paid up to $1.925B for Versanis. @AstraZeneca acquired SixPeaks. Large pharma isn't just investing in weight loss. They're investing in what comes after. 👉 Full analysis: insights.patentvest.com/the-… #GLP1 #Obesity #Biotech
39
The next blockbuster obesity opportunity may not be another GLP-1. It may be that the therapies are designed to improve GLP-1s.
1
15
→ 20 programs in development → Lilly acquired Versanis for up to $1.925B → AstraZeneca acquired SixPeaks →Valuable GLP-1 combination IP emerging New PatentVest Pulse: insights.patentvest.com/the-… #GLP1 #Obesity #Biotech #Pharma
19
Our latest case study with Docana explores how we helped define freedom-to-operate boundaries, identify competitive whitespace, and build a long-term IP strategy. Read full case study: patentvest.com/case-studies/…
1
19
We’ve just published a new case study with Docana on navigating IP strategy in the competitive AI/LLM space. From patent landscape analysis to freedom-to-operate strategy, the goal was strategic clarity before scaling. Read more: patentvest.com/case-studies/…
16
The obesity-drug race may not be won by the best molecule. It may be won by the best IP.
1
11
New PV Pulse Report: The Triple-Agonist Race: Retatrutide, Twenty-Seven Programs, and the Hidden Patent War Behind the Next Obesity Market. insights.patentvest.com/the-…
52
In our latest PatentVest newsletter, our COO, Javier Chamorro, shares how IP strategy, prosecution processes, and AI are reshaping what it means to build defensible patents. If you're building technology, this is worth a read. 👇 linkedin.com/pulse/building-…
1
16
The amylin land grab has started 🧵 @novonordisk , @EliLillyandCo , @Roche , @pfizer , @abbvie , @AstraZeneca , @StructureTx , @Viking_VKTX All building positions. That level of alignment is rare.
1
44
Every major pharma company sees it. That’s why they’re moving now. Before the landscape locks in.
1
11
We broke down the full landscape, programs, players, and where defensible positions are actually being built in our latest PatentVest Pulse report. 👇Here: insights.patentvest.com/http…
22